Jennifer C. Smith-Parker, Director of Insights at BioSpace, spoke with Dr. Marc Hedrick, President and CEO of Plus Therapeutics, and Dr. Philip Kantoff, Co-founder and CEO of Convergent Therapeutics, in a Denatured podcast episode released on Apr. 2.
The discussion focused on recent developments in the use of alpha-emitting isotopes for cancer treatment and how these advances may shape the future of biotechnology.
During the episode, Smith-Parker asked about new methods to address supply chain challenges related to isotopes. The guests shared their perspectives on how radiotherapeutics could represent a significant leap forward in biotech applications for cancer care.
Hedrick and Kantoff provided insights into both the scientific progress being made with isotopes as well as logistical issues facing researchers and manufacturers in this field.
The podcast also included a disclaimer stating: "The views expressed in this discussion by guests are their own and do not represent those of their organizations."
Looking ahead, the experts suggested that continued innovation in radiotherapeutic technology could have far-reaching effects for patients and industry stakeholders.
